Our technology is based on the capture of extracellular vesicles (microvesicles and exosomes) with our patented novel lead compound.
By not targeting a specific biomarker and with a simpler laboratory process which preserves the integrity of exosomes, we provide a broader set of applications both for diagnostic and therapeutic purposes, across multiple health conditions.
Detection of the biomarker podocalyxin from exosome collected with our technology from the urine of people with diabetic nephropathy.
PEOPLE WITH DIABETES, NORMOALBUMINURIA AND MACROALBUNINURIA
Our technology detects CD41, a biomarker located in exosomes and microvesicles, in plasma from people with diabetes, normoalbuminuria and macroalburninuria.